Objective:To systematically evaluate the clinical efficacy of Sofren Injection combined with conventional therapy in treatment of heart failure. MethodA computer-based search of Chinese and English databases was conducted on December 2018 to collect literatures on clinical randomized controlled trials (RCTs) with Sofren Injection in the treatment of heart failure. Quality evaluation was performed on the literatures included according to Cochrane Handbook for Systematic Reviews of Interventions. Using RevMan 5.3 and Stata 12.0, the clinical efficacy of Sofren Injection in the treatment of heart failure was analyzed by meta-analysis.  Results:Totally 15 RCTs with 1,9 patients were included. The results of meta-analysis showed that compared with conventional therapy, Sofren Injection combined with conventional therapy had better comprehensive efficacy in treating heart failure [OR=3.59,5% CI (2.45,5.26), P＜0.000 01], increased the left ventricular ejection fraction (LVEF) [SMD=1.10,5% CI (0.98, 1.23), P＜0.000 01], improved the left ventricular end-diastolic diameter [SMD=-0.9,5% CI (-1.32, -0.48), P＜0.000 01], reduced the levels of plasma brain natriuretic peptide (BNP) (SMD=-1.43,5% CI (-2.19, -0.68), P＜0.000 01) and N-terminal B-type BNP precursor (SMD=-4.89, 95% CI (-7.50, -2.29), P＜0.000 01), and increased the walking distance in 6-minute walking test [MD=29.26,5% CI (20.90,7.61), P＜0.000 01].  Conclusion:The efficacy of Sofren Injection combined with conventional therapy is superior to that of conventional therapy alone in treatment of heart failure. However, the quality and quantity of the literatures included in the analysis are limited, and the conclusion needs to be verified with follow-up studies.